Modulus Discovery, Inc. (“Modulus”), a preclinical stage technology-driven drug discovery company, will present at the 41st Annual J.P. Morgan Healthcare Conference. The J.P. Morgan Healthcare Conference, the largest and most informative healthcare investment symposium in the industry, will be held in San Francisco on January 8-12, 2023.

Roy Kimura, Modulus co-founder and CEO, will present on January 11, 2023 at 2:30 pm PST and give an update on the company’s cutting-edge simulation-based drug discovery platform and its portfolio of small-molecule drug discovery programs in chronic inflammation, autoimmune diseases, and oncology. Following the event, the company will be available for meetings with interested parties to further describe details of its unique discovery capabilities and lead programs currently in preclinical studies.

Comment from S. Roy Kimura, CEO
“We are delighted to be speaking again at the J.P. Morgan Conference. Over the past year, we have made significant progress in our lead programs including the achievement of in vivo proof of concept in multiple disease models in chronic inflammation, autoimmune diseases, and oncology. We are also excited to introduce our latest proprietary drug discovery technology, ModBind™, a new simulation algorithm that enables accurate, fast, and scalable predictions of ligand efficacy using a fundamentally different theoretical approach to other available methods in the industry.”

About Modulus Discovery, Inc.
Modulus Discovery, Inc., is a preclinical-stage technology-driven drug discovery firm with offices in Tokyo and Boston. The company is pursuing its unique portfolio of small-molecule discovery programs and collaborations through integration of its unique core biology insights, cutting-edge simulation platform, and scalable networked operations. Modulus is focused on the efficient delivery of breakthrough medicines for patients and their families with unmet medical needs in areas including oncology, chronic inflammation, autoimmune disorders, infectious diseases, and rare genetic conditions.